Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza A/H5N1 vaccine in at-risk adults
NCT00417560Phase 2Withdrawn
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Jan 2007
- Primary completion
- Aug 2010
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label, single-arm trial of Inactivated Influenza A/H5N1 Vaccine in Influenza A virus infection (IAV), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Frequencies and severities of Adverse Events at 56 days, Geometric Mean Titers of serum neutralizing and HAI antibodies at 56 days and 1 more. Planned start Jan 2007; status: withdrawn.
02
Drugs
Inactivated Influenza A/H5N1 Vaccine
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT00417560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417560.